Lilly Acquires Mental Health Innovator | Business and Finance News

Eli Lilly is making a bold move into the future of mental health by acquiring AtaiBeckley for $6.75 in cash per share, with potential upside of $2.50 more if milestones are hit. AtaiBeckley’s groundbreaking therapies—like BPL-003, a psychedelic-derived drug in late-stage trials for treatment-resistant depression—aim to rebuild neural connections, not just tweak neurotransmitters. With Lilly’s massive resources and global reach, this deal could accelerate breakthroughs for patients who’ve been left behind by traditional antidepressants. Closing in Q3, this acquisition signals a major shift toward next-gen mental health treatments rooted in brain biology, not just symptom management. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d674400fb3ee9242